节点文献

仑伐替尼联合局部疗法治疗PD-L1基因阳性门脉癌栓程氏分型Ⅰ~Ⅲ型肝癌疗效观察

Curative Effect of Lenvatinib Combined with Locoregional Therapy on PD-L1-positive Hepatocellular Carcinoma Patients with Type Ⅰ-Ⅲ Portal Vein Tumor Thrombus According to Cheng’s Classification

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 陈珑刘宇杰田素青王翠英何冬雷

【Author】 CHEN Long;LIU Yujie;TIAN Suqing;WANG Cuiying;HE Donglei;Department of Oncology, Sanya Central Hospital, The Third People’s Hospital of Hainan Province;Department of Radiation Oncology, Peking University Third Hospital;Department of Gastrointestinal Cancer Surgery, The First Affiliated Hospital of Hainan Medical College;

【机构】 三亚中心医院(海南省第三人民医院)肿瘤治疗中心北京大学第三医院肿瘤放疗科海南医学院第一附属医院胃肠肿瘤外科

【摘要】 目的比较仑伐替尼联合局部疗法与局部疗法治疗PD-L1基因阳性门脉癌栓程氏分型Ⅰ~Ⅲ型肝癌患者的临床疗效。方法仑伐替尼联合局部疗法组患者口服仑伐替尼12 mg每天一次(体重≥60 kg)或8 mg每天一次(体重<60 kg)。局部治疗组患者仅行局部治疗。回顾性分析两组患者临床资料和预后。结果联合组和局部治疗组CR+PR分别为78.1%和53.6%。联合组有效率和疾病控制率均高于局部疗法组(P<0.05);生存分析结果提示:联合组患者的总生存率高于局部疗法组,差异有统计学意义(P<0.05)。结论仑伐替尼联合局部疗法治疗PD-L1基因阳性门脉癌栓程氏分型Ⅰ~Ⅲ型肝癌疗效较好,患者总生存率较局部疗法高。

【Abstract】 Objective To compare curative effect between lenvatinib combined with locoregional therapy and locoregional therapy on PD-L1-positive hepatocellular carcinoma patients with type Ⅰ-Ⅲ portal vein tumor thrombus according to Cheng’s classification.Methods The patients in lenvatinib combined with locoregional therapy group received orally-administered lenvatinib at a dose of 12 mg qd for patients≥60 kg or 8 mg qd for patients<60 kg.The locoregional therapy group only received locoregional therapy.We retrospectively analyzed the clinical data and prognosis of two groups.Results The CR+PR were 78.1% and 53.6% in the combination group and locoregional therapy group,respectively (P<0.05).The response rate,disease control rate and overall survival of the combination group were higher than those in the locoregional therapy group (P<0.05).Conclusion The curative effect and overall survival of lenvatinib combined with locoregional therapy is better than locoregional therapy on PD-L1-positive hepatocellular carcinoma patients with type Ⅰ-Ⅲ portal vein tumor thrombus according to Cheng’s classification.

  • 【文献出处】 肿瘤防治研究 ,Cancer Research on Prevention and Treatment , 编辑部邮箱 ,2022年01期
  • 【分类号】R735.7
  • 【被引频次】1
  • 【下载频次】135
节点文献中: 

本文链接的文献网络图示:

本文的引文网络